Clinical Trial Detail

NCT ID NCT04375527
Title Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Jonsson Comprehensive Cancer Center
Indications

skin melanoma

Therapies

Binimetinib + Nivolumab

Age Groups: senior adult

Additional content available in CKB BOOST